Clinical trials: Lymphoma, Large B-Cell, Diffuse
Diffuse Large B-cell Lymphoma
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
The purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (R-B)combination in elderly patients affected by diffuse large B-cell lymphoma and defined as frail according to CGA.
- Trial name
- NCT01990144
- Testing
- Bendamustine+Rituximab
- Where
- 52 sites in Italy
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma
Imaging Apoptosis for Lymphoma Treatment Response
Apoptosis is a specific form of cell death that leads to clearance of dead cells without causing inflammation or injury to normal adjacent tissues.
- Trial name
- NCT05048732
- Testing
- 18F-FluorApoTrace
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Acute Leukemia, Acute Lymphoblastic Leukemia
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies).
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT04195633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Diffuse Large B-cell Lymphoma
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients.
- Trial name
- NCT04026100
- Testing
- CTA101
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lymphoma Diffuse Large B-cell
Occupational Exposure to Pesticides in the Prognosis of Lymphomas
The link between the products of synthetic chemistry and cancer is at the heart of much research. Recent work has identified the use of plant protection agents by farmers as a risk factor for developing non-Hodgkin lymphoma…
- Trial name
- ProLyPhy (NCT02898870)
- Where
- France
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Diffuse Large B-cell Lymphoma(DLBCL)
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
Zanubrutinib is a highly specific, potent new Bruton's tyrosine kinase （BTK） inhibitor, with minimal off-target inhibition of other kinases.
- Trial name
- NCT05189197
- Testing
- Zanubrutinib + R-CHOP
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Fudan University
Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell
a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
The main purpose of this study is to explore the sequential therapeutic effect and evaluate the safety of anti-CD19 or anti-CD20 CAR-T cells briging HSCT in the treatment of relapse/refractory B cell malignancies.
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma，Malignant
- Trial name
- NCT02846584
- Testing
- CD19 or CD20 CAR T cells briging HSCT
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Southwest Hospital, China
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Communication Skills Intervention to Promote Transition Into Survivorship
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
- Trial name
- NCT01483664
- Where
- 9 sites in United States
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematologic Malignancy
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM)…
- Trial name
- SANGUINE (NCT05735704)
- Testing
- Blood sampling for HemaChip screening/diagnostic testing
- Where
- 4 sites in Czechia, Greece and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Diffuse Large B Cell Lymphoma
Characterization and Clinical Impact of the Gut Microbiota in Lymphoma
The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut microbiome of healthy controls.
- Trial name
- NCT06161896
- Testing
- Stool samples
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lars Møller Pedersen